坎托菲茨杰拉德公司:维持Vera Therapeutics(VERA.US)评级,由增持调整至增持评级,目标价由107.00美元调整至100.00美元。Vera Therapeutics(VERA.US)公司简介:Vera Therapeutics Inc是一家临床阶段的生物技术公司。该公司专注于为患有严重免疫疾病的患者开发变革性疗法并将其商业化。该公司的候选产品是atacicept,是一种融合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.